84 related articles for article (PubMed ID: 20659064)
21. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
Bolin K; Mörk AC; Willers S; Lindgren B
Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and cost-effectiveness of smoking cessation courses in the statutory health insurance: a review].
Rasch A; Greiner W
Gesundheitswesen; 2009 Nov; 71(11):732-8. PubMed ID: 19492280
[TBL] [Abstract][Full Text] [Related]
23. The cost effectiveness of pharmacotherapies for smoking cessation: necessary but not sufficient?
Shanahan M; Doran C; Gates J; Shakeshaft A; Mattick RP
Appl Health Econ Health Policy; 2003; 2(2):76-8. PubMed ID: 14619277
[No Abstract] [Full Text] [Related]
24. The value of more information: a commentary on Stewart et al.
Lillard DR
Soc Sci Med; 2010 Dec; 71(11):1910-2; discussion 1912-3. PubMed ID: 20888107
[No Abstract] [Full Text] [Related]
25. Should smoking cessation cost a packet? A pilot randomized controlled trial of the cost-effectiveness of distributing nicotine therapy free of charge.
Dey P; Foy R; Woodman M; Fullard B; Gibbs A
Br J Gen Pract; 1999 Feb; 49(439):127-8. PubMed ID: 10326267
[TBL] [Abstract][Full Text] [Related]
26. Smoking cessation in a blue-collar population: results from an evidence-based pilot program.
Ringen K; Anderson N; McAfee T; Zbikowski SM; Fales D
Am J Ind Med; 2002 Nov; 42(5):367-77. PubMed ID: 12382249
[TBL] [Abstract][Full Text] [Related]
27. PHARMAC and tobacco control in New Zealand: government policy 'up in smoke'.
Holt S; Harwood M; Aldington S; Beasley R
N Z Med J; 2005 Jun; 118(1216):U1502. PubMed ID: 15937536
[TBL] [Abstract][Full Text] [Related]
28. Possible methodological reason for the finding that "Neither tax increase nor reimbursement reduced health disparities": comment on the article by by Over et al. (2014).
van der Deen FS; Wilson N; Blakely T
Nicotine Tob Res; 2014 Jul; 16(7):1030. PubMed ID: 24638851
[No Abstract] [Full Text] [Related]
29. New AHCPR guideline targets and cost of smoking cessation programs.
Campbell S
Health Care Strateg Manage; 1996 Jun; 14(6):16-7. PubMed ID: 10157810
[No Abstract] [Full Text] [Related]
30. Reply to the comment by Van der Deen et al.: "Possible methodological reason for the finding that 'Neither tax increase nor reimbursement reduced health disparities'".
Over EA; Feenstra TL; Hoogenveen RT; Droomers M; Uiters E; van Gelder BM
Nicotine Tob Res; 2014 Jul; 16(7):1031-2. PubMed ID: 24759894
[No Abstract] [Full Text] [Related]
31. A cost-effectiveness evaluation of single and combined smoking cessation interventions in Texas.
Hill A
Tex Med; 2006 Aug; 102(8):50-5. PubMed ID: 17115560
[No Abstract] [Full Text] [Related]
32. Smoking cessation and prevention.
Jones JL
J S C Med Assoc; 1991 Dec; 87(12):592-3. PubMed ID: 1762429
[No Abstract] [Full Text] [Related]
33. Cost-effectiveness analyses of health promotion programs: a case study of smoking prevention and cessation among Dutch students.
Vijgen SM; van Baal PH; Hoogenveen RT; de Wit GA; Feenstra TL
Health Educ Res; 2008 Apr; 23(2):310-8. PubMed ID: 17675649
[TBL] [Abstract][Full Text] [Related]
34. [Determining the possibility of collecting reliable data for use in decision making in health care on the example of cost-effectiveness analysis of methods used in smoking cessation].
Bała M
Przegl Lek; 2004; 61(10):1180-3. PubMed ID: 15794284
[TBL] [Abstract][Full Text] [Related]
35. Smoking cessation services: coverage and utilization.
Manag Care Interface; 1999 Aug; 12(8):81-2. PubMed ID: 10621098
[No Abstract] [Full Text] [Related]
36. [Smoking cessation in general practice. A new program is over 50% effective].
Hering T; Bölcskei P
MMW Fortschr Med; 2002 May; 144(18):50-1. PubMed ID: 12422708
[No Abstract] [Full Text] [Related]
37. If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands.
Vemer P; Rutten-van Mölken MP; Kaper J; Hoogenveen RT; van Schayck CP; Feenstra TL
Addiction; 2010 Jun; 105(6):1088-97. PubMed ID: 20659063
[TBL] [Abstract][Full Text] [Related]
38. Cessation in the use of tobacco - pharmacologic and non-pharmacologic routines in patients.
Quist-Paulsen P
Clin Respir J; 2008 Jan; 2(1):4-10. PubMed ID: 20298298
[TBL] [Abstract][Full Text] [Related]
39. [Can the society afford not to subsidize smoking cessation?].
Larsson M; Larsson K; Gilljam H; Curman B
Lakartidningen; 2002 Jun; 99(23):2665-6. PubMed ID: 12101625
[No Abstract] [Full Text] [Related]
40. Cost-benefit analysis involving addictive goods: contingent valuation to estimate willingness-to-pay for smoking cessation.
Weimer DL; Vining AR; Thomas RK
Health Econ; 2009 Feb; 18(2):181-202. PubMed ID: 18566968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
